Member access

4-Traders Homepage  >  Shares  >  London Stock Exchange  >  Vernalis plc    VER   GB00B3Y5L754

VERNALIS PLC (VER)

0
Delayed Quote. Delayed London Stock Exchange - 04/23 11:35:05 am
35.5 GBp   +2.90%
1d ago VERNALIS : Research wins Queen’s Award for Enterprise
04/15 VERNALIS : Notice of Annual Report and AGM
04/07 VERNALIS : Directors Granted Share Options (DIRECTOR DEALINGS)
SummaryQuotesChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Vernalis plc
Researches and develops pharmaceuticals

Vernalis Plc is a research and development stage pharmaceutical company.

The company provides pharmaceutical products for a range of medical disorders.

It focuses on de novo fragment and structure based drug discovery and pre clinical and clinical development.

The group has one marketed product, frovatriptan, for the acute treatment of migraines, an exclusive licensing agreement to develop and commercialize multiple novel products focused on the U.S. prescription cough and cold market as well as eight programmes in its NCE development pipeline.

It has significant expertise in fragment and structure based drug discovery which it leverages to enter into collaborations with other pharmaceutical companies.

The group product pipeline for central nervous system diseases include V158866 for the treatment of a range of pain disorders, which is in Phase I trial and V81444, an A2A receptor antagonists for the treatment for Parkinson's disease, which is in pre-clinical stage development.

The company was founded by Keith G. McCullagh in 1986 and is headquartered in Wokingham, the United Kingdom.
Sales per Businesses
20122013Delta
GBP (in Million)%GBP (in Million)%
Pharmaceutical14.62100%14.08100% -3.78%
Sales per Regions
20122013Delta
GBP (in Million)%GBP (in Million)%
Rest of Europe12.7487.2%10.6475.5% -19.78%
North America1.8212.4%3.0521.7% +40.41%
Rest of the World0.0340.2%0.3742.7% +90.91%
United Kingdom0.0210.1%0.0200.1% -5%
Officers and Executives
NameAgeOfficer SinceTitle
Ian Garland48-Chief Executive Officer & Executive Director
Peter John Fellner, PhD71-Non-Executive Chairman
David MacKney46-Chief Financial Officer & Executive Director
Mike Wood--Research Director
Allan J. Baxter, PhD64-Independent Non-Executive Director
Carol C. Ferguson67-Senior Independent Non-Executive Director
Nigel Sheail48-Independent Non-Executive Director
Kevin Kissane58-Secretary & General Counsel
Nerida Scott, PhD--Director-Business Development & Licensing
Surperformance© rating of Vernalis plc
Overall rating In sector In country
Trading Rating
Investor Rating
Growth (Revenue)
Valuation
Finances
Profitability
Earnings quality
Business Predictability
PER - - -
Potential
Yield - - -
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision - - -
4 months Revenue revision
1 year Revenue revision
More Ratings
Sector
Healthcare
Biotechnology / Pharmaceuticals
 Biotechnology / Pharmaceuticals
  Pharmaceuticals - Diversified
Advertisement
Sector Pharmaceuticals - Diversified
Trading RatingInvestor Rating
JOHNSON & JOHNSON
ROCHE HOLDING LTD..
NOVARTIS AG
PFIZER INC.
MERCK & CO., INC.
Sector Pharmaceuticals - Diversified
Company contact information
Vernalis Plc
100 Berkshire Place
Wharfedale Road
Winnersh, Berkshire RG41 5RD

Phone : +44.118.938.0000
Fax : +44.118.938.0001
Web : www.vernalis.com
© 2014 Factset   
Dynamic quotes  
ON
| OFF